Aravive — Versartis — Technical Presentation (September 2016)
15 slides from Aravive's technical presentation, Sep 2, 2016
Slide 1: Somavaratan (VRS-317) Treatment for Pediatric GHD: VISTA Study Results at 2.5 Years
George Bright1, Wayne V. Moore2, Huong Jil Nguyen3, Gad B. Kletter4, Bradley S. Miller5, Patricia Y. Fechner6, David Ng7, Eric Humphriss1, Jeffrey L. Cleland1 1Versartis, Inc, Menlo Park, CA; 2Children's Mercy Hospital and University of Missouri-Kansas City, Kansas City, MO; 3Sierra Medical Research
Slide 2: Disclosures
Disclosures George Bright, MD, and Jeffrey Cleland, PhD, are consultants and hold equity interests in Versartis, Inc Huong Jil Nguyen, MD, has received research funding from Versartis, Inc Bradley S. Miller, MD, PhD, has received grants from Alexion Pharmaceuticals, Inc., Endo Pharmaceuticals, Genen
Slide 3: Recombinant Human Growth Hormone for Treatment of Pediatric GHD
Recombinant Human Growth Hormone (rhGH) for Treatment of Pediatric Growth Hormone Deficiency (GHD) Therapeutic potential of daily rhGH is well established and has been the primary treatment for pediatric GHD for three decades1,2 Current challenges with daily rhGH preparations include burden of daily
Slide 4: rhGH in Pediatric GHD: Decreasing HV After 1st Year
rhGH in Pediatric GHD: Decreasing HV After 1st Year Romer et al. Hormone Research. 2009;72:359-369. Copyright © 2009 Karger Publishers, Basel, Switzerland. Used with permission. Mean HV Over 7 Years of rhGH Treatment in Children with GHD At constant dose, ~1.7 cm/year decline in HV from Year 1 to Ye
Slide 5: Somavaratan (VRS-317) Increased Time on Target
Somavaratan (VRS-317) Increased Time on Target XTEN1 Long Tail of Hydrophilic Amino Acids Reduce Kidney Filtration XTEN2 Short Tail of Hydrophilic Amino Acids Reduce Receptor Mediated Clearance rhGH Same Sequence as Approved Products In clinical development for treatment of children and adults with
Slide 6: Somavaratan: Clinical Experience
Somavaratan: Clinical Experience Phase 1 - Adults1 30- to 60-fold increase in elimination half-life and longer IGF-I responses, compared with daily rhGH (N=50) Dose-proportional increases in magnitude and duration of IGF-I responses for up to 1 month after a single dose No study drug related serious
Slide 7: VISTA Study Design
VISTA Study Design 1Moore et al. J Clin Endocrinol Metab. 2016;101(3):1091-1097. 5.0 mg/kg Monthly 3.5 mg/kg Twice-Monthly 6–12 Months 12–30 Months (ongoing) 0–6 Months Somavaratan Dose Interval Phase 2a (Repeat Dose) Long-Term Safety Study 2.5 mg/kg Twice-Monthly 1.15 mg/kg Weekly 5.0 mg/kg Monthly
Slide 8: Patient Demographics and Baseline Characteristics
Patient Demographics and Baseline Characteristics Subjects Enrolled in Phase 2a (n=64) Baseline Age, yeaers, mean (SD) 7.8 (2.4) Gender, n (%) Female 27 (42%) Male 37 (58%) Race, n (%) White 53 (83%) Asian 5 (8%) Black or African American 3 (5%) American Indian or Alaska native 1 (2%) Other 2 (3%) H
Slide 9: Results: Pharmacodynamics
Results: Pharmacodynamics Mean Mean ± SD Range During Year 2, IGF-I samples drawn every 3 months, alternating between “peak” (3-5 days after injection) and “trough” (end of dosing cycle), measured by mass spectroscopy In all patients receiving 3.5 mg/kg twice-monthly, 8 subjects had peak IGF-I SDS e
Slide 10: Results: Efficacy – Height Velocity and Height-SDS
Results: Efficacy – Height Velocity and Height-SDS Mean Height Velocity (HV) and Height-SDS in All Evaluable Patients at 2 Years (n=57) Mean HV ±SD, cm/year Increasing the somavaratan dose to 3.5 mg/kg twice-monthly resulted in Year 2 HV comparable to Year 1 and continued improvement in HT-SDS Lower
Slide 11: Results: Efficacy – Bone, Height, and Chronological Age
Results: Efficacy – Bone, Height, and Chronological Age Mean increase in bone age and height age exceeded years on study, while differences between chronological and bone age decreased over time Years Bone and Height Age Over Time Chronological Age vs. Bone Age Bone Age Height Age Baseline Year 2 Ba
Slide 12: Year 2 Efficacy Comparators
Year 2 Efficacy Comparators Selection of the somavaratan 3.5 mg/kg twice-monthly dose is supported by similarities in second year HV (7.83 cm/year) to US estimates (7.9 cm/year) from NCGS Study Second Year Height Velocity (cm/year) Somavaratan – 3.5 mg/kg twice-monthly All subjects with 2-year data
Slide 13: Results: Safety
Results: Safety Treatment-Related Adverse Events (AEs) Occurring in >1 Subject Adverse Event, n (%) Treatment Period Months 0-6 (n=64) Months 6-12 (n=60) Months 12-18 (n=57) Months 18-24 (n=53) Months 24-30 (n=48) All AEs 34 (53) 10 (17) 6 (11) 4 (8) 6 (13) Injection site pain 31 (48) 6 (10) 2 (4) 1
Slide 14: Conclusions
Conclusions Phase 3 dose selection supported by VISTA study results for subjects switched to 3.5 mg/kg twice-monthly Mean peak IGF-I SDS at Phase 3 dose was in upper half of normal range Catch-up growth supported by mean increase in bone age and height age exceeding years on study, with gap between
Slide 15: Acknowledgments
Acknowledgments Investigators & Study Coordinators Patients and their Caregivers Clinical Operations Leslie Jones, ResearchPoint Global Morgan Seaman, ResearchPoint Global Naureen Sheikh, PhD, Versartis, Inc. Lynda Chaplin, Versartis, Inc.